CNMD vs. SLNO, INMD, LIVN, TMDX, BLFS, ITGR, MASI, CLDX, ASTH, and DCPH
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include Soleno Therapeutics (SLNO), InMode (INMD), LivaNova (LIVN), TransMedics Group (TMDX), BioLife Solutions (BLFS), Integer (ITGR), Masimo (MASI), Celldex Therapeutics (CLDX), Astrana Health (ASTH), and Deciphera Pharmaceuticals (DCPH). These companies are all part of the "medical" sector.
CONMED (NYSE:CNMD) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.
CONMED has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the S&P 500.
97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.8% of CONMED shares are owned by company insiders. Comparatively, 23.7% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Soleno Therapeutics had 2 more articles in the media than CONMED. MarketBeat recorded 13 mentions for Soleno Therapeutics and 11 mentions for CONMED. CONMED's average media sentiment score of 0.85 beat Soleno Therapeutics' score of 0.41 indicating that CONMED is being referred to more favorably in the media.
CONMED presently has a consensus target price of $107.86, suggesting a potential upside of 53.69%. Soleno Therapeutics has a consensus target price of $55.60, suggesting a potential upside of 18.65%. Given CONMED's higher probable upside, research analysts clearly believe CONMED is more favorable than Soleno Therapeutics.
CONMED has a net margin of 6.53% compared to Soleno Therapeutics' net margin of 0.00%. CONMED's return on equity of 13.78% beat Soleno Therapeutics' return on equity.
CONMED has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics received 273 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 71.22% of users gave Soleno Therapeutics an outperform vote while only 41.38% of users gave CONMED an outperform vote.
Summary
CONMED beats Soleno Therapeutics on 11 of the 17 factors compared between the two stocks.
Get CONMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
